SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down – Time to Sell?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) gapped down prior to trading on Wednesday . The stock had previously closed at $3.76, but opened at $3.61. SELLAS Life Sciences Group shares last traded at $3.6150, with a volume of 1,096,005 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.00.

SELLAS Life Sciences Group Trading Down 2.8%

The stock has a fifty day moving average price of $3.36 and a 200 day moving average price of $2.30. The firm has a market cap of $520.62 million, a price-to-earnings ratio of -13.07 and a beta of 2.27.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. On average, sell-side analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current year.

Insider Buying and Selling at SELLAS Life Sciences Group

In other news, Director Katherine Bach Kalin acquired 63,400 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average cost of $1.59 per share, with a total value of $100,806.00. Following the acquisition, the director owned 104,400 shares in the company, valued at approximately $165,996. This represents a 154.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Axxcess Wealth Management LLC acquired a new position in SELLAS Life Sciences Group in the 3rd quarter valued at approximately $26,000. Larson Financial Group LLC bought a new position in SELLAS Life Sciences Group in the fourth quarter worth $26,000. BNP Paribas Financial Markets boosted its stake in SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after buying an additional 9,299 shares in the last quarter. Blair William & Co. IL acquired a new stake in SELLAS Life Sciences Group during the second quarter worth $35,000. Finally, Concurrent Investment Advisors LLC bought a new stake in SELLAS Life Sciences Group in the 4th quarter valued at $38,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.